Az NKGen Biotech és a Graf Acquisition IV egyesülése 160 millió dolláros üzletben

NKGen Biotech and Graf Acquisition IV announced late Friday that they entered into a definitive merger agreement at a pro forma enterprise value of at least $160 million. If approved, upon closing NKGen Biotech is expected to list on the a major exchange under the ticker symbol NKGN.

NKGen is a clinical-stage biotechnológia company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer (“NK”) cell therapeutics.

The pro forma enterprise value is based on $145 million in pre-money equity value plus conversion to equity at closing of at least $15 million of outstanding private convertible securities and accrued interest. Graf and NKGen will pursue new PIPE funding prior to closing the deal and NKMax will backstop up to $25 million cash funded at $10 per share. The transaction has a minimum $50 million cash condition to close.

Proceeds are expected to be used toward the funding of the combined company’s business and Phase II trials and operations through Q2 2025. Tovább.

Forrás: NKGen Biotech and Graf Acquisition IV Merging in 0M Deal

• SEO által támogatott tartalom és PR terjesztés. Erősödjön még ma.
• Platoblockchain. Web3 metaverzum intelligencia. Felerősített tudás. Hozzáférés itt.
• A jövő pénzverése – Adryenn Ashley. Hozzáférés itt.
• Forrás: https://spacfeed.com/nkgen-biotech-and-graf-acquisition-iv-merging-in-160m-deal?utm_source=rss&utm_medium=rss&utm_campaign=nkgen-biotech-and-graf-acquisition-iv-merging-in-160m-deal